Protagenic Therapeutics, Inc. 8-K Report: Financial Insights & Stock Updates

Here are the key pieces of information extracted from the provided financial report section:

1. Company Identification:

• Company Name: Protagenic Therapeutics, Inc.
• CIK Number: 0001022899
• Address: 149 Fifth Avenue, Suite 500, New York, NY 10010
• Phone Number: 212-994-8200

2. Filing Information:

• Filing Type: 8-K
• Filing Date: January 15, 2025
• SEC File Number: 001-12555
• IRS Number: 06-1390025

3. Stock Information:

• Common Stock Ticker: PTIX (NASDAQ)
• Warrants Ticker: PTIXW (NASDAQ)

4. Reporting Context:

• The report covers information as of January 15, 2025.
• The context includes common stock and common stock warrants.

5. Units of Measurement:

• Financial data is reported in USD (United States Dollar) and shares.

6. Structural Elements:

• The report uses XBRL (eXtensible Business Reporting Language) for structured data, indicating that it is designed for electronic filing and analysis.

7. Segment Reporting:

• There are explicit members reported in the context of common stock and common stock warrants, which may hint at different classes or types of equity instruments within the company.

8. Regulatory Compliance:

• The document adheres to the US GAAP (Generally Accepted Accounting Principles) standards, as indicated by the namespaces included in the XML.

Insights:

• Protagenic Therapeutics, Inc. is actively reporting its financial information as of a specific date, which implies ongoing compliance with SEC regulations.
• The presence of both common stock and warrants indicates that the company may be leveraging various financial instruments to raise capital or incentivize investment.
• The structured nature of the filing suggests a focus on transparency and detailed reporting, which could be advantageous for investors seeking clear and accessible financial information.